Arrowhead Reports Positive Phase 2a Trial Results For Patients With Hepatitis B
September 24, 2015 at 19:37 PM EDT
Shares of Arrowhead surged 21% after announcing positive phase 2a trial results for its Hepatitis B drug ARC-520.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.